HomeNews

News

BIOCAD has presented the results of efficacy evaluation of the Russian immuno-oncology product prolgolimab for the treatment of melanoma

In the evening of June 21, 2021, leading Russian and international cancer experts presented the results of a three-year efficacy study of the Russian...

SK Bioscience to invest $132 million to beef up vaccine production capacity

SK Bioscience said the investment is meant to increase the production capacity of the production line based in Andong, about 270 kilometers south of Seoul.

Cuban Soberana 02 vaccine against the coronavirus shows 62% efficacy

Vérez described the result as “very comforting,” because it has been obtained in a scenario of circulation “of the most worrying variants due to their transmissibility.”

Chairman of the Board of Directors of Promomed Group Petr Bely on the company’s developments

On March 15, 2021, Russian President Vladimir Putin awarded the Chairman of the Board of Directors of Promomed Group Petr Bely the Order of...

GDP combined with new technology and infrastructure, will help ensure global integrity

Governments around the world struggle with the logistical challenges of procuring, deploying and administering vaccines at scale. To deliver the vaccines, pharmaceutical companies, logistical partners...

Eisai and BMS Enter Into Strategic Collaboration for MORAb-202 Antibody Drug Conjugate

Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses.
spot_img

Expert Articles

spot_img